Skip to main content
SpringerLink
Log in

Gerichtete Evolution in der Wirkstoff- und Antikörperentwicklung

Vom Nobelpreis zur breiten klinischen Anwendung

Directed evolution in drug and antibody development

From the Nobel Prize to broad clinical application

  • Schwerpunkt: Monoklonale Antikörper
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Kombinatorische Verfahren haben sich in den letzten Jahren als Alternative zum rationalen Design in der Wirkstoffforschung etabliert, insbesondere dann, wenn keine strukturelle Information zur Verfügung steht. Hier wird das Prinzip vorgestellt, dass originär von zwei Wissenschaftlern und einer Wissenschaftlerin entwickelt und 2018 mit dem Nobelpreis für Chemie ausgezeichnet wurde. Weiterhin wird die Anwendung im Bereich der monoklonalen Antikörper diskutiert.

Abstract

Combinatorial procedures have become established in recent years as alternatives to rational design in drug research, particularly when no structural information is available. This article presents the principle that was originally developed by three scientists and was honored with the Nobel Prize for Chemistry in 2018. Furthermore, the application in the field of monclonal antibodies is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Weiterführende Literatur

  1. Arnold FH (1998) Design by directed evolution. Acc Chem Res 31:125–131

    Article  CAS  Google Scholar 

  2. Buss NA, Henderson SJ, McFarlane M, Shenton JM, de Haan L (2012) Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol 12:615–622

    Article  CAS  PubMed  Google Scholar 

  3. Cantani A (2008) Pediatric allergy, asthma and immunology. Springer, Berlin, Heidelberg, S 1–219

    Google Scholar 

  4. Collins J (1997) Phage display. Ann Rev Comb Chem Mol Div 1:210–262

    CAS  Google Scholar 

  5. Cwirla S, Peters E, Bartett R, Dower W (1990) Peptides on phage: a vast library of peptides for identifying ligands. Proc Natl Acad Sci USA 87:6378–6382

    Article  CAS  PubMed  Google Scholar 

  6. Ecker DM, Jones SD, Levine HL (2015) The therapeutic monoclonal antibody market. mAbs 7:9–14

    Article  CAS  PubMed  Google Scholar 

  7. Giver L, Arnold FH (1998) Combinatorial protein design by in vitro recombination. Curr Opin Chem Biol 2:335–338

    Article  CAS  PubMed  Google Scholar 

  8. Gregoret LM, Sauer RT (1998) Tolerance of a protein helix to multiple alanine and valine substitutions. Fold Des 3:119–126

    Article  CAS  PubMed  Google Scholar 

  9. Harris JL, Craik CS (1998) Engineering enzyme specificity. Curr Opin Chem Biol 2:127–132

    Article  CAS  PubMed  Google Scholar 

  10. Hoffmüller U, Schneider-Mergener J (1998) In vitro evolution and selection of proteins: ribosome display for larger libraries. Angew Chem Int Ed 37:3241–3243

    Article  Google Scholar 

  11. Hubner B, Haensler M, Hahn U (1999) Modification of ribonuclease T1 by random mutagenesis of the substrate binding segment. Biochemistry 38:1371–1376

    Article  CAS  PubMed  Google Scholar 

  12. Jermutus L, Ryabova LA, Plückthun A (1998) Recent advances in producing and selecting functional proteins by using cell-free translation. Curr Opin Biotechn 9:534–548

    Article  CAS  Google Scholar 

  13. Jucovic M, Poteete AR (1998) Delineation of an evolutionary salvage pathway by compensatory mutations of a defective lysozyme. Prot Sci 7:2200–2209

    Article  CAS  Google Scholar 

  14. Katz BA (1997) Structural and mechanistic determination of affinity and specificity of ligands discovered or engineered by phage display. Ann Rev Biophys Biomol Struct 26:27–45

    Article  CAS  Google Scholar 

  15. Klein C, Schaefer W, Regula JT (2016) The use of CrossMAb technology for the generation of bi- and multispecific antibodies. mAbs 8:1010–1020

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kuchner O, Arnold FH (1997) Directed evolution of enzyme catalysts. Trends Biotechn 15:523–530

    Article  CAS  Google Scholar 

  17. Kumar R, Parray HA, Shrivastava T, Sinha S, Luthra K (2019) Phage display antibody libraries: a robust approach for generation of recombinant human monoclonal antibodies. Int J Biol Macromol 135:907–918

    Article  CAS  PubMed  Google Scholar 

  18. Lowman HB (1997) Bacteriophage display and discovery of peptides leads for drug development. Ann Rev Biophys Biomol Struct 26:401–424

    Article  CAS  Google Scholar 

  19. Macbeath G, Kast P, Hilvert D (1998) Exploring sequence constraints on an interhelical turn using in vivo selection for catalytic activity. Prot Sci 7:325–335

    Article  CAS  Google Scholar 

  20. Sauer RT (1996) Protein folding from a combinatorial perspective. Fold Des 1:R27–R30

    Article  CAS  PubMed  Google Scholar 

  21. Scott J, Smith GP (1990) Searching for peptide ligands with an epitope library. Science 249:386–390

    Article  CAS  PubMed  Google Scholar 

  22. Sharma S, Tammela J, Wang X et al (2007) Characterization of a putative ovarian oncogene, elongation factor 1A, isolated by panning a synthetic phage display single-chainvariable fragment library with cultured human ovarian cancer cells. Clin Cancer Res 13(19):2007

    Article  CAS  Google Scholar 

  23. Singh S, Kumar NK, Dwiwedi P, Charan J, Kaur R, Sidhu P, Chugh VK (2018) Monoclonal antibodies: a review. Curr Clin Pharmacol 13:85–99

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fakultät für Lebenswissenschaften, Institut für Biochemie, Universität Leipzig, Brüderstraße 34, 04103, Leipzig, Deutschland

    A. G. Beck-Sickinger

Authors
  1. A. G. Beck-Sickinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. G. Beck-Sickinger.

Ethics declarations

Interessenkonflikt

A.G. Beck-Sickinger gibt an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von der Autorin keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

J. Mössner, Leipzig

A. Neubauer, Marburg

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Beck-Sickinger, A.G. Gerichtete Evolution in der Wirkstoff- und Antikörperentwicklung. Internist 60, 1014–1020 (2019). https://doi.org/10.1007/s00108-019-00675-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-019-00675-1

Schlüsselwörter

Keywords

Search

Navigation